HOUSTON, Aug. 20, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced its participation in two separate presentations at
the Masters in Aesthetics Symposium being held at the
Intercontinental in San Diego,
California later this month.
In the session titled, "New Technologies to Enhance Tattoo
Removal", Dr. Vic Ross will be
sharing details regarding the Company's clinical efficacy in tattoo
removal and method of treatment to accelerate the removal of
tattoos. In Dr. Matt Avram's
session, titled, "Treatments for Non-Invasive Fat Removal, Body
Contouring and Muscle Stimulation: What's New & What Works?",
he will include recent data from the Company's pivotal cellulite
trial and approach to the treatment of cellulite.
"We are extremely pleased to be demonstrating the full
capabilities and potential of our aesthetics solutions at the
Masters in Aesthetics Symposium," commented Christopher Capelli, MD, founder, President and
CEO of Soliton. "We believe this event provides our Company the
opportunity to showcase the benefits and clinical efficacy of both
our cellulite therapy and tattoo removal solutions. We look forward
to further driving the clinical development of both solutions as we
prepare to launch our improved RAP device early next year."
The Company's technology has not yet been cleared by the FDA for
cellulite treatment and is not yet available for sale in
the United States.
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
Details of the Presentations are as Follows:
Title of session: New Technologies to Enhance Tattoo Removal
Presenter: Dr. Vic Ross
Timing: Saturday, August
29th at 11:40 AM –
11:50 AM ET
Location: Intercontinental San Diego, San
Diego, USA
Title of session: Treatments for Non-Invasive Fat Removal, Body
Contouring and Muscle Stimulation: What's New & What Works?
Presenter: Dr. Matt Avram
Timing: Sunday, August
30th at 2:30 PM –
2:45 PM ET
Location: Intercontinental San Diego, San
Diego, USA
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton has completed a clinical study using the RAP device to
improve the appearance of cellulite and is investigating potential
additional capabilities of the RAP technology. The device is
currently cleared in the United
States only for use in tattoo removal and is not yet cleared
for use to address cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Drs. Ross and
Avram to present Soliton clinical data at the symposium and for the
Company to receive clearance of the cellulite indication, and to
successfully launch our product. These statements relate to
future events, future expectations, plans and prospects. Although
Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
actual results or outcomes may prove to be materially different
from the expectations expressed or implied by such forward-looking
statements. Soliton has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' "would,"
''should,'' ''approximately'' or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, including those discussed in our filings with the
Securities and Exchange Commission ("SEC"), including under the
heading " Risk Factors" in the Form 10-K for year ended
December 31, 2019 filed with the SEC
and as updated in our Form 10-Q filings and in our other filings
with the SEC. Any forward-looking statements contained in this
release speak only as of its date. Soliton undertakes no obligation
to update any forward-looking statements contained in this release
to reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-announces-presentations-at-masters-in-aesthetics-symposium-301115180.html
SOURCE Soliton, Inc.